Medical Cost of Upper Respiratory Tract Infections in Children in Ambulatory Care

• Published in: Value in health regional issues 2021-12, Vol.26, p.1-9
• Main Authors: Sánchez Choez, Xavier, Loaiza Martínez, María, Vaca Tatamuez, Viviana, López Peña, Marco, Manzano Pasquel, Andrea, Jimbo Sotomayor, Ruth
• Format: Article
• Language: English
• Subjects: ambulatory care; cost; upper respiratory tract infection
• ISSN: 2212-1099; 2212-1102
• DOI: 10.1016/j.vhri.2020.10.001

The aim of this study was to estimate the direct cost per episode and the annual cost for upper respiratory tract infection (URTI) in children in Ambulatory Health Centers of the Ministry of Public Health (MSP) of Ecuador. A cost of illness study with a provider perspective was carried out through a micro-costing of health resources and valuated in international dollars. Medical visits, laboratory tests, imaging examinations, and other procedures were valued using the tariff framework of services for the National Health System, and for prescribed medication a reported cost registry of pharmacy purchases made in the year of study was used. We included 380 electronic health records of children. We found a re-consultation rate of 22.89%, a medicine prescription rate of 95.52%, and an antibiotic prescription rate of 45.26%. The first medical consultation accounted for 71.9% of the total cost of URTI, the following visits accounted for 11.82%, and medication accounted for 14.68%. Antibiotics accounted for 58.92% of the total cost of medication. The direct medical cost to the MSP of Ecuador of 1 episode of URTI in children in primary care was around I$37.28 (2017 dollars) (95% CI: I$35.81-I$38.75). The total cost of URTI cases in children to the MSP in 2017 was at least I$50.478 million (2017 dollars) (95% CI I$48.527m-I$52.523m). Re-consultation and the prescription of medication represent an important component of the direct cost of medical care of URTI. •Upper respiratory tract infections in ambulatory care inflict a great impact on healthcare systems.•Cost-of-illness studies with a provider perspective can help to design cost containment policies.•Cost containment policies that are focused on appropriate prescription and rational use of antibiotics can be cost saving.